New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors
FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …
the potential to be both more efficacious and safer than the currently available direct oral …
Contemporary management and clinical course of acute pulmonary embolism: the COPE study
C Becattini, G Agnelli, AP Maggioni… - Thrombosis and …, 2023 - thieme-connect.com
Background New diagnosis, risk stratification, and treatment strategies became recently
available for patients with acute pulmonary embolism (PE) leading to changes in clinical …
available for patients with acute pulmonary embolism (PE) leading to changes in clinical …
[HTML][HTML] How well do European patients understand cancer-associated thrombosis? A patient survey
A Falanga, C Girvalaki, M Monreal, JC Easaw… - Cancer Treatment and …, 2022 - Elsevier
Ongoing concerns regarding the morbidity and mortality from cancer-associated thrombosis
led the European Cancer Patient Coalition (ECPC), the voice of cancer patients across …
led the European Cancer Patient Coalition (ECPC), the voice of cancer patients across …
[HTML][HTML] Provoked versus unprovoked venous thromboembolism: findings from GARFIELD‐VTE
Introduction Venous thromboembolism (VTE) has a long‐term risk of recurrence, dependent
on the presence or absence of provoking risk factors at the time of the event. Objective To …
on the presence or absence of provoking risk factors at the time of the event. Objective To …
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE
Introduction Randomized controlled trials have shown that direct oral anticoagulants
(DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the …
(DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the …
[HTML][HTML] Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis
DT Vlazny, AK Pasha, W Kuczmik… - Journal of Thrombosis …, 2021 - Elsevier
Background Isolated, distal deep vein thrombosis (IDDVT) is thought to have low rates of
propagation, embolization, and recurrence compared with proximal DVT (PDVT), but the …
propagation, embolization, and recurrence compared with proximal DVT (PDVT), but the …
[HTML][HTML] Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey
Background Anticoagulant treatment of splanchnic (SVT) and cerebral vein thrombosis
(CVT) can be challenging due to the rarity of these conditions, the concomitantly high …
(CVT) can be challenging due to the rarity of these conditions, the concomitantly high …
Long-term outcome of chronic thromboembolic pulmonary hypertension in the era where direct oral anticoagulants become available
Chronic thromboembolic pulmonary hypertension (CTEPH) is a disease with a poor
prognosis. Indeed, a 3-year mortality rate was reported to be 90% in a series of 49 patients …
prognosis. Indeed, a 3-year mortality rate was reported to be 90% in a series of 49 patients …
On-treatment comparative effectiveness of vitamin K antagonists and direct oral anticoagulants in GARFIELD-VTE, and focus on cancer and renal disease
Background Direct oral anticoagulants (DOACs) provide a safe, effective alternative to
vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via …
vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via …
Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis
SG Fronas, AEA Dahm, HS Wik, CT Jørgensen… - Blood …, 2020 - ashpublications.org
Guidelines suggest using empiric low-molecular-weight heparin if the diagnostic workup of
deep vein thrombosis (DVT) is expected to be delayed. The role of direct oral anticoagulants …
deep vein thrombosis (DVT) is expected to be delayed. The role of direct oral anticoagulants …